Sign Up to Join G-Med

Already a member? Log in.
Got a Patient Case Dilemma ?

G-Med is a closed community for verified physicians only 

Click to Ask Your Colleagues & Get Answers

Featured Posts

Cancer Incidence Up for Adolescents and Young Adults

THURSDAY, Sept. 17, 2020 (HealthDay News) -- Among adolescents and young adults (AYAs), cancer incidence increased during 2007 to 2016, according to a report published online Sept. 17 in CA: A Cancer Journal for Clinicians.

Kimberly D. Miller, M.P.H., from the American Cancer Society in Atlanta, and colleagues examined population-based cancer incidence and mortality for AYAs by age group (15 to 19, 20 to 29, and 30 to 39 years), sex, and race/ethnicity.

The researchers note that there will be about 89,500 new cancer cases and 9,270 cancer deaths in AYAs in 2020. During the most recent decade (2007 to 2016), overall cancer incidence increased in all AYA age groups, mainly driven by thyroid cancer. In most age groups, incidence also increased for several cancers linked to obesity, including kidney, uterine corpus, and colorectum. In those aged 15 to 29 years, rates declined dramatically for melanoma (4 to 6 percent annually). During 2008 through 2017, overall cancer mortality decreased by 1 percent annually across age and sex groups, apart from women aged 30 to 39 years who had stable rates. Across age groups, five-year relative survival in AYAs was similar for all cancers combined (range, 83 to 86 percent) but varied widely for some cancers.

"AYAs diagnosed with cancer also continue to face numerous challenges in health care access during early life transitions, which can negatively impact the timeliness of and adherence to treatment," the authors write.

Abstract/Full Text (subscription or payment may be required)

EPA, DHA Supplementation Linked to Reduced Risk for MI, CHD

THURSDAY, Sept. 17, 2020 (HealthDay News) -- Supplementation with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is associated with a reduced risk for myocardial infarction (MI) and coronary heart disease (CHD) events, according to a meta-analysis published online Sept. 17 in the Mayo Clinic Proceedings.

Aldo A. Bernasconi, Ph.D., from the Global Organization for EPA and DHA Omega-3s in Salt Lake City, and colleagues conducted a meta-analysis and meta-regression of randomized controlled trials with EPA/DHA supplementation to quantify their effect on cardiovascular disease (CVD) prevention. Data were included for 40 studies with 135,267 participants.

The researchers found that supplementation was associated with a reduced risk for MI, CHD events, fatal MI, and CHD mortality (relative risks [95 percent confidence intervals], 0.87 [0.80 to 0.96], 0.90 [0.84 to 0.97], 0.65 [0.46 to 0.91], and 0.91 [0.85 to 0.98], respectively; high certainty number needed to treat: 272, 192, 128, and 431, respectively) but not with CVD events (relative risk, 0.95; 95 percent confidence interval, 0.90 to 1.00). For CVD events and MI, the effect was dose-dependent.

"The current study presents strong evidence that EPA+DHA supplementation is an effective strategy for the prevention of certain CVD outcomes, and that for CVD events and MI, the protective effect appears to increase with dosage," the authors write. "Authoritative bodies issuing intake recommendations and health care providers need to consider taking these results into account."

Abstract/Full Text (subscription or payment may be required)

Survey: About Seven in 10 Adults Interested in COVID-19 Vaccine

THURSDAY, Sept. 17, 2020 (HealthDay News) -- Nearly seven in 10 U.S. adults are "definitely" or "probably" willing to get a COVID-19 vaccine, according to research published online Aug. 20 in Vaccine.

Paul L. Reiter, Ph.D., M.P.H., from the College of Public Health at The Ohio State University in Columbus, and colleagues conducted an online survey of 2,006 U.S. adults in May 2020 to better understand participants' willingness to get a COVID-19 vaccine (i.e., vaccine acceptability).

The researchers found that 69 percent of participants were willing to get a COVID-19 vaccine ("definitely" or "probably"), but willingness was only 55 percent among Black respondents. Vaccine acceptability was higher if participants thought their health care provider would recommend vaccination (relative risk [RR], 1.73) or if they were moderate (RR, 1.09) or liberal (RR, 1.14) in their political leaning. Vaccine willingness was also higher if participants reported higher levels of perceived likelihood of getting a COVID-19 infection in the future (RR, 1.05), perceived severity of COVID-19 infection (RR, 1.08), and perceived effectiveness of a COVID-19 vaccine (RR, 1.46). Vaccine acceptability was lower among non-Latinx Black respondents (RR, 0.81) and those reporting a higher level of perceived potential vaccine harm (RR, 0.95).

"You hear a lot of talk of vaccination and the benefits of herd immunity, the idea that when enough people have resistance to a virus it reduces the threat to the entire population," Reiter said in a statement. "At 70 percent, we may or may not get there."

Abstract/Full Text

Reinfection from Covid . Return to work

Hello,  I work in Mexico ,  I want to know your opinion , on when is the best time to return to my office ? (pediatrician) .  Im reinfected from Covid,  I had my first infection three months ago with PCR (+) but abs in three different times (-) .   I have mild syntoms,  headache, cough,  weakness,  no smell and taste.   What labs you reccomend me to do?  And if only I wait the 15 days aisle .  Thanks. 

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

The 4C Mortality Score uses 8 variables -- age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea level, and C reactive protein -- to compute a score that ranges from zero to 21 points. The score then stratifies patients into risk groups, with scores of zero to 3 indicating a low risk of mortality, scores of 4 to 8 indicating intermediate risk, scores of 9 to 14 indicating a high risk of death, and scores ≥15 indicating the highest mortality risk.


Ask / Share